Literature DB >> 27459230

The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Robert L Rosenfield1, David A Ehrmann1.   

Abstract

Polycystic ovary syndrome (PCOS) was hypothesized to result from functional ovarian hyperandrogenism (FOH) due to dysregulation of androgen secretion in 1989-1995. Subsequent studies have supported and amplified this hypothesis. When defined as otherwise unexplained hyperandrogenic oligoanovulation, two-thirds of PCOS cases have functionally typical FOH, characterized by 17-hydroxyprogesterone hyperresponsiveness to gonadotropin stimulation. Two-thirds of the remaining PCOS have FOH detectable by testosterone elevation after suppression of adrenal androgen production. About 3% of PCOS have a related isolated functional adrenal hyperandrogenism. The remaining PCOS cases are mild and lack evidence of steroid secretory abnormalities; most of these are obese, which we postulate to account for their atypical PCOS. Approximately half of normal women with polycystic ovarian morphology (PCOM) have subclinical FOH-related steroidogenic defects. Theca cells from polycystic ovaries of classic PCOS patients in long-term culture have an intrinsic steroidogenic dysregulation that can account for the steroidogenic abnormalities typical of FOH. These cells overexpress most steroidogenic enzymes, particularly cytochrome P450c17. Overexpression of a protein identified by genome-wide association screening, differentially expressed in normal and neoplastic development 1A.V2, in normal theca cells has reproduced this PCOS phenotype in vitro. A metabolic syndrome of obesity-related and/or intrinsic insulin resistance occurs in about half of PCOS patients, and the compensatory hyperinsulinism has tissue-selective effects, which include aggravation of hyperandrogenism. PCOS seems to arise as a complex trait that results from the interaction of diverse genetic and environmental factors. Heritable factors include PCOM, hyperandrogenemia, insulin resistance, and insulin secretory defects. Environmental factors include prenatal androgen exposure and poor fetal growth, whereas acquired obesity is a major postnatal factor. The variety of pathways involved and lack of a common thread attests to the multifactorial nature and heterogeneity of the syndrome. Further research into the fundamental basis of the disorder will be necessary to optimally correct androgen levels, ovulation, and metabolic homeostasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27459230      PMCID: PMC5045492          DOI: 10.1210/er.2015-1104

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  517 in total

1.  Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a.

Authors:  Diego H Castrillon; Lili Miao; Ramya Kollipara; James W Horner; Ronald A DePinho
Journal:  Science       Date:  2003-07-11       Impact factor: 47.728

Review 2.  Polycystic ovary syndrome: a changing perspective.

Authors:  S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1989-07       Impact factor: 3.478

3.  Opposite effects of 17-β estradiol and testosterone on mitochondrial biogenesis and adiponectin synthesis in white adipocytes.

Authors:  Gabriela Capllonch-Amer; Isabel Lladó; Ana M Proenza; Francisco J García-Palmer; Magdalena Gianotti
Journal:  J Mol Endocrinol       Date:  2014-03-06       Impact factor: 5.098

4.  Digit ratio (2D:4D) in newborns: influences of prenatal testosterone and maternal environment.

Authors:  T Ventura; M C Gomes; A Pita; M T Neto; A Taylor
Journal:  Early Hum Dev       Date:  2012-09-25       Impact factor: 2.079

5.  The post-endocytotic fate of the gonadotropin receptors is an important determinant of the desensitization of gonadotropin responses.

Authors:  R S Bhaskaran; M Ascoli
Journal:  J Mol Endocrinol       Date:  2005-04       Impact factor: 5.098

6.  Developmental regulation of follicle-stimulating hormone receptor messenger RNA expression in the baboon fetal ovary.

Authors:  Nicholas C Zachos; Reinhart B Billiar; Eugene D Albrecht; Gerald J Pepe
Journal:  Biol Reprod       Date:  2002-12-27       Impact factor: 4.285

7.  Substrate specificity of the placental microsomal aromatase.

Authors:  W Gibb; J C Lavoie
Journal:  Steroids       Date:  1980-11       Impact factor: 2.668

8.  Eukaryotic initiation factor 5A plays an essential role in luteinizing hormone receptor regulation.

Authors:  Bindu Menon; Thippeswamy Gulappa; K M J Menon
Journal:  Mol Endocrinol       Date:  2014-09-12

9.  Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries.

Authors:  Stephen Franks; Lisa J Webber; Micaela Goh; Anne Valentine; Davinia M White; Gerard S Conway; Steven Wiltshire; Mark I McCarthy
Journal:  J Clin Endocrinol Metab       Date:  2008-06-17       Impact factor: 5.958

10.  Development of a novel cell based androgen screening model.

Authors:  Carmela Campana; Juilee Rege; Adina F Turcu; Vincenzo Pezzi; Celso E Gomez-Sanchez; Diane M Robins; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2015-11-12       Impact factor: 4.292

View more
  222 in total

1.  Age at Onset of Metabolic Syndrome Among Women With and Without Polycystic Ovary Syndrome-Like Status.

Authors:  Qing Peng; Carrie A Karvonen-Gutierrez; John F Randolph; Bin Nan; Daniel McConnell; Siobán D Harlow
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

Review 2.  Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?

Authors:  Milica Popovic; Gideon Sartorius; Mirjam Christ-Crain
Journal:  Semin Immunopathol       Date:  2019-05-28       Impact factor: 9.623

3.  Endometrial progesterone receptor isoforms in women with polycystic ovary syndrome.

Authors:  Min Hu; Juan Li; Yuehui Zhang; Xin Li; Mats Brännström; Linus R Shao; Håkan Billig
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 4.  Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies.

Authors:  Manmohan K Kamboj; Andrea E Bonny
Journal:  Transl Pediatr       Date:  2017-10

5.  Chronically elevated androgen and/or consumption of a Western-style diet impairs oocyte quality and granulosa cell function in the nonhuman primate periovulatory follicle.

Authors:  Cecily V Bishop; Taylor E Reiter; David W Erikson; Carol B Hanna; Brittany L Daughtry; Shawn L Chavez; Jon D Hennebold; Richard L Stouffer
Journal:  J Assist Reprod Genet       Date:  2019-06-11       Impact factor: 3.412

Review 6.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

7.  Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.

Authors:  Danalea V Skarra; Angelina Hernández-Carretero; Alissa J Rivera; Arya R Anvar; Varykina G Thackray
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

8.  Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies.

Authors:  Panagiotis Anagnostis; Rodis D Paparodis; Julia K Bosdou; Christina Bothou; Djuro Macut; Dimitrios G Goulis; Sarantis Livadas
Journal:  Endocrine       Date:  2021-06-26       Impact factor: 3.633

9.  Polycystic ovary syndrome and its possible association with sleep complaints : PCOS and sleep.

Authors:  Ellen M S Xerfan; Anamaria S Facina; Monica L Andersen; Helena Hachul; Sergio Tufik; Jane Tomimori
Journal:  Arch Womens Ment Health       Date:  2021-06-25       Impact factor: 3.633

10.  Combined androgen excess and Western-style diet accelerates adipose tissue dysfunction in young adult, female nonhuman primates.

Authors:  Oleg Varlamov; Cecily V Bishop; Mithila Handu; Diana Takahashi; Sathya Srinivasan; Ashley White; Charles T Roberts
Journal:  Hum Reprod       Date:  2017-09-01       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.